Literature DB >> 21385880

Apoptosis is the essential target of selective pressure against p53, whereas loss of additional p53 functions facilitates carcinoma progression.

Xiangdong Lu1, Chunyu Yang, Chaoying Yin, Terry Van Dyke, Karl Simin.   

Abstract

The high frequency of p53 mutation in human cancers indicates the important role of p53 in suppressing tumorigenesis. It is well established that the p53 regulates multiple, distinct cellular functions such as cell-cycle arrest and apoptosis. Despite intensive studies, little is known about which function is essential, or if multiple pathways are required, for p53-dependent tumor suppression in vivo. Using a mouse brain carcinoma model that shows high selective pressure for p53 inactivation, we found that even partially abolishing p53-dependent apoptosis by Bax inactivation was sufficient to significantly reduce the selective pressure for p53 loss. This finding is consistent with previous reports that apoptosis is the primary p53 function selected against during Eμ-myc-induced mouse lymphoma progression. However, unlike observed in the Eμ-myc-induced lymphoma model, attenuation of apoptosis is not sufficient to phenocopy the aggressive tumor progression associated with complete loss of p53 activity. We conclude that apoptosis is the primary tumor suppressive p53 function and the ablation of additional p53 pleiotropic effects further exacerbates tumor progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385880      PMCID: PMC3078190          DOI: 10.1158/1541-7786.MCR-10-0277

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  31 in total

Review 1.  p53: puzzle and paradigm.

Authors:  L J Ko; C Prives
Journal:  Genes Dev       Date:  1996-05-01       Impact factor: 11.361

2.  Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.

Authors:  R L Ludwig; S Bates; K H Vousden
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

3.  Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

Authors:  N Rampino; H Yamamoto; Y Ionov; Y Li; H Sawai; J C Reed; M Perucho
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

4.  Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.

Authors:  S Rowan; R L Ludwig; Y Haupt; S Bates; X Lu; M Oren; K H Vousden
Journal:  EMBO J       Date:  1996-02-15       Impact factor: 11.598

5.  Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.

Authors:  S Krajewski; C Blomqvist; K Franssila; M Krajewska; V M Wasenius; E Niskanen; S Nordling; J C Reed
Journal:  Cancer Res       Date:  1995-10-01       Impact factor: 12.701

6.  p53-dependent apoptosis suppresses tumor growth and progression in vivo.

Authors:  H Symonds; L Krall; L Remington; M Saenz-Robles; S Lowe; T Jacks; T Van Dyke
Journal:  Cell       Date:  1994-08-26       Impact factor: 41.582

7.  Bax-deficient mice with lymphoid hyperplasia and male germ cell death.

Authors:  C M Knudson; K S Tung; W G Tourtellotte; G A Brown; S J Korsmeyer
Journal:  Science       Date:  1995-10-06       Impact factor: 47.728

8.  Radiation-induced cell cycle arrest compromised by p21 deficiency.

Authors:  J Brugarolas; C Chandrasekaran; J I Gordon; D Beach; T Jacks; G J Hannon
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

9.  Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.

Authors:  B Hsu; M C Marin; A K el-Naggar; L C Stephens; S Brisbay; T J McDonnell
Journal:  Oncogene       Date:  1995-07-06       Impact factor: 9.867

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  1 in total

1.  MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas.

Authors:  Malini Mukherjee; Gouqing Ge; Nenggang Zhang; David G Edwards; Pavel Sumazin; Shyam K Sharan; Pulivarthi H Rao; Daniel Medina; Debananda Pati
Journal:  Oncogene       Date:  2013-11-25       Impact factor: 9.867

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.